Bayer wins Norway cancer firm Algeta with raised $2.9 bln offer

OSLO Thu Dec 19, 2013 2:47am EST

Related Topics

OSLO Dec 19 (Reuters) - Bayer has raised its offer for Norway's Algeta, its partner for a new prostate cancer treatment, to 362 Norwegian crowns per share, valuing Algeta's equity at 2.1 billion euros ($2.9 billion).

Bayer in late November offered to pay 336 Norwegian crowns per Algeta share. ($1 = 0.7266 euros) (Reporting by Gwladys Fouche, editing by Terje Solsvik)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.